Clinical Performance of Two Commercial, Daily Disposable Contact Lenses
NCT ID: NCT05010512
Last Updated: 2022-11-08
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
112 participants
INTERVENTIONAL
2021-08-31
2021-10-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Comparison of Two Daily Disposable Contact Lenses - Pilot Study 3
NCT04942925
Clinical Comparison of Two Daily Disposable Contact Lenses
NCT04865354
Two Daily Disposable Contact Lenses in Symptomatic Patients
NCT03628599
Comparison of Two Daily Disposable Lenses
NCT04013789
Evaluation of Delefilcon A Contact Lenses
NCT06884202
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DT1, then Infuse
Delefilcon A contact lenses worn first, with kalifilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 (-0/+3) days on a daily wear, daily disposable basis.
Delefilcon A contact lenses
Commercially available silicone hydrogel contact lenses used as indicated
Kalifilcon A contact lenses
Commercially available silicone hydrogel contact lenses used as indicated
Infuse, then DT1
Kalifilcon A contact lenses worn first, with delefilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 (-0/+3) days on a daily wear, daily disposable basis.
Delefilcon A contact lenses
Commercially available silicone hydrogel contact lenses used as indicated
Kalifilcon A contact lenses
Commercially available silicone hydrogel contact lenses used as indicated
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Delefilcon A contact lenses
Commercially available silicone hydrogel contact lenses used as indicated
Kalifilcon A contact lenses
Commercially available silicone hydrogel contact lenses used as indicated
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 3 months of contact lens wearing experience;
* Less than or equal to 0.75 diopter (D) astigmatism in each eye;
* Best Corrected Visual Acuity (BCVA) better than or equal to 20/25 in each eye.
Exclusion Criteria
* Monovision and/or multifocal lens wearer;
* Routinely sleeps in habitual contact lenses.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alcon Research
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trial Lead, Vision Care
Role: STUDY_DIRECTOR
Alcon Research, LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alcon Investigator 6355
Orlando, Florida, United States
Alcon Investigator 6418
Tallahassee, Florida, United States
Alcon Investigator 3950
Bloomington, Illinois, United States
Alcon Investigator 6614
Franklin Park, Illinois, United States
Alcon Investigator 6583
Eden Prairie, Minnesota, United States
Alcon Investigator 3382
Wyomissing, Pennsylvania, United States
Alcon Investigator 6353
Memphis, Tennessee, United States
Alcon Investigator 2786
Memphis, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLU484-P002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.